
HEB
Other · Other · $4.5M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2019
EPS trend, 90 days to now · -3425.0% over 90 days · 30-day revisions 2 up, 0 down
Beat estimates in 0 of the last 1 reported quarter.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 15, 2018 | Time not confirmed | -0.06 | -0.07 | -16.7% |
Hemispherx Biopharma, Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic…